🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

339 results for “Astra” Clear

  1. Esomeprazole Magnesium, NEXIUM 10 mg gastro-resistant granules for oral suspension, sachet, Esomeprazole Magnesium

    AstraZeneca AB

    Erosive Esophagitis

    phase 3 small molecule active

    1 trial

  2. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  3. Forxiga 10 mg film-coated tablets, Baxdrostat Placebo, Baxdrostat, Baxdrostat, Baxdrostat

    AstraZeneca AB

    Prevention of Heart failure

    phase 3 small molecule active

    1 trial

  4. GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN

    AstraZeneca AB

    Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder

    phase 3 small molecule active

    1 trial

  5. GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  6. Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  7. HYDROCORTISONE, PREDNISONE ACETATE, ENZALUTAMIDE, DEXAMETHASONE ACETATE, PREDNISONE, Opevesostat, ABIRATERONE ACETATE, DEXAMETHASONE, HYDROCORTISONE , HYDROCORTISONE, FLUDROCORTISONE, ABIRATERONE ACETATE, PREDNISOLONE, HYDROCORTISONE, FLUDROCORTISONE ACETATE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  8. Herzuma 420 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, Perjeta 420 mg concentrate for solution for infusion, CYCLOPHOSPHAMIDE, DS-8201a, PACLITAXEL, DOXORUBICIN, Herzuma 150 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE

    AstraZeneca AB

    Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)

    phase 3 small molecule active

    1 trial

  9. IBRANCE 75 mg film-coated tablets, GOSERELIN ACETATE, Placebo to match camizestrant, Placebo to match anastrozole, camizestrant, ABEMACICLIB, Placebo to match letrozole, IBRANCE 100 mg film-coated tablets, Arimidex® 1 mg Filmtabletten, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, LETROZOLE, LEUPRORELIN ACETATE, ABEMACICLIB, Camizestrant, ABEMACICLIB

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  10. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion., DURVALUMAB, MYCOPHENOLATE MOFETIL, Placebo, OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., INFLIXIMAB

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., Mycophenolate Mofetil 500 mg film-coated tablets, Nexavar 200 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Advanced hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  13. IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, LENVIMA 4 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  14. INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

  15. INFLIXIMAB, DS-8201a, AZD6738, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients with non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  16. INFLIXIMAB, FOLINIC ACID, IMFINZI 50 mg/mL concentrate for solution for infusion., DOCETAXEL, PLACEBO, OXALIPLATIN, FLUOROURACIL, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).

    phase 3 small molecule active

    1 trial

  17. INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, MYCOPHENOLATE MOFETIL, DEXTROSE BP, SODIUM CHLORIDE

    AstraZeneca AB

    Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation)

    phase 3 small molecule active

    1 trial

  18. INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Rilvegostomig, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Lung Cancer

    phase 3 small molecule active

    1 trial

  19. INFLIXIMAB, MYCOPHENOLATE MOFETIL, Placebo, BEVACIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  20. INFLIXIMAB, Rilvegostomig, MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB , BEVACIZUMAB

    AstraZeneca AB

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  21. INFLIXIMAB, SODIUM CHLORIDE, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, IMJUDO 20 mg/ml concentrate for solution for infusion., DEXTROSE BP

    AstraZeneca AB

    Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)

    phase 3 small molecule active

    1 trial

  22. Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

  23. JNJ-56021927, Prednison acis 5 mg, Tabletten, ZYTIGA 250 mg tablets, placebo to match JNJ-56021927/Apalutamide, -

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  24. JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources